Older adults · North Carolina
Studies for adults 50 and older in North Carolina
These studies set a minimum age of 50 or older in their official record. Many look at conditions more common with age, and some vaccine and memory studies specifically need older participants.
40 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteersOvernight stay mentioned
The Osteoarthritis Prevention Study
Wake Forest University
- Location
- Winston-Salem, NC + 1 other US site
- Eligibility basics
- Ages 50+ · Women only
- RecruitingHealthy volunteersPhase 3
A Study on the Efficacy of a Vaccine Against Influenza in Adults ≥65 Years of Age
GlaxoSmithKline
- Location
- Charlotte, NC + 130 other US sites
- Eligibility basics
- Ages 65+
- RecruitingPhase 3
Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica
Sanofi
- Location
- Charlotte, NC + 46 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 2
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
Merck Sharp & Dohme LLC
- Location
- Matthews, NC + 34 other US sites
- Eligibility basics
- Ages 50–85
- RecruitingPhase 1/Phase 2
A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
Sanofi
- Location
- Wake Forest, NC + 30 other US sites
- Eligibility basics
- Ages 60+
- RecruitingPhase 3
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Hoffmann-La Roche
- Location
- Greensboro, NC + 67 other US sites
- Eligibility basics
- Ages 50–90
- RecruitingPhase 3
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Location
- Matthews, NC + 56 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 3
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
Bristol-Myers Squibb
- Location
- Morehead City, NC + 10 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 2
A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette);
Genentech, Inc.
- Location
- Durham, NC + 14 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 3
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
Amgen
- Location
- Raleigh, NC + 54 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
Bristol-Myers Squibb
- Location
- Morehead City, NC + 21 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
Celgene
- Location
- Charlotte, NC + 31 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
Hoffmann-La Roche
- Location
- Asheville, NC + 52 other US sites
- Eligibility basics
- Ages 50–85
- RecruitingPhase 4
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
Genentech, Inc.
- Location
- Hickory, NC + 1 other US site
- Eligibility basics
- Ages 50+
- RecruitingPhase 2/Phase 3
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
EyeBiotech Ltd.
- Location
- Greensboro, NC + 66 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 2/Phase 3
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Janssen Research & Development, LLC
- Location
- Asheville, NC + 44 other US sites
- Eligibility basics
- Ages 60+
- RecruitingPhase 2
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
Intra-Cellular Therapies, Inc.
- Location
- Charlotte, NC + 17 other US sites
- Eligibility basics
- Ages 55+
- RecruitingPhase 2
Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
ACADIA Pharmaceuticals Inc.
- Location
- Chapel Hill, NC + 27 other US sites
- Eligibility basics
- Ages 55–84
- RecruitingPhase 3
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
Adverum Biotechnologies, Inc.
- Location
- Asheville, NC + 78 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 3
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Location
- Greensboro, NC + 43 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 2
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
ONL Therapeutics
- Location
- Cary, NC + 55 other US sites
- Eligibility basics
- Ages 55+
- RecruitingPhase 3
Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
Dompé Farmaceutici S.p.A
- Location
- Durham, NC + 13 other US sites
- Eligibility basics
- Ages 50–80
- RecruitingPhase 1
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
Eli Lilly and Company
- Location
- Durham, NC + 4 other US sites
- Eligibility basics
- Ages 50–85
- RecruitingPhase 2/Phase 3
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
EyeBiotech Ltd.
- Location
- Asheville, NC + 51 other US sites
- Eligibility basics
- Ages 50+